share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

SEC announcement ·  May 9 05:03
Summary by Futu AI
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.